Top of this document
Go directly to navigation
Go directly to page content

person 6

Aubrey de Grey

Biomedical Gerontologist, Author, Co-founder & Chief Science Officer of SENS Foundation

Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK. He is the Co-Founder and Chief Science Officer of the SENS foundation, a research institute that focuses on the development of what he has termed "Strategies for Engineered Negligible Senescence" (SENS) - a tissue-repair strategy intended to rejuvenate the human body and thereby allow an indefinite lifespan. To this end, he has identified seven types of molecular and cellular "damage" caused by essential metabolic processes; SENS is a proposed panel of therapies to repair this damage.

Aubrey’s innovative and provocative views on aging have made him an in-demand speaker worldwide, both among the science community and the general public. He has also been interviewed by a variety of respected news sources, including 60 Minutes, BBC, the New York Times, Fortune Magazine, the Washington Post, TED, Popular Science and the Colbert Report.

In 2007 Aubrey published his book, Ending Aging, bringing his ideas to a wider audience.

About the SENS Foundation (www.sens.org)
SENS Foundation was launched in March, 2009 as a new and independent organization, with a mission to develop, promote and ensure widespread access to regenerative medicine solutions to the disabilities and diseases of aging.

Our work builds upon many important research programs that were initiated by Methuselah Foundation. Methuselah Foundation is an organization with a core mission of ending age-related disease through awareness, education, scientific research, and direct community outreach. Its activities have included the Mprize mouse longevity prize program, and SENS research initiatives. It continues under the leadership of its Founder and CEO Dave Gobel.

SENS Foundation is a non-profit organization which works to develop, promote and ensure widespread access to regenerative medicine solutions to the disabilities and diseases of aging. Our focus is on the Strategies for Engineered Negligible Senescence (SENS) identified by our Chief Science Officer, Dr Aubrey de Grey, combining direct research efforts with education, affiliation and outreach programs. We support key research through our own institute and through a variety of affiliated universities and research organizations.

Our research is governed by a strategic agenda to demonstrate the feasibility of SENS and regenerative medicine approaches, and therefore drive broader involvement. We are already assembling a world class team of advisors; we shall continue to build on the successful biennial Aging (US) and SENS (UK) Conferences; we are expanding affiliations to include non-profits with complementary missions, research organizations, government support, and technology transfer with mainstream biotechnology companies; and we are working hard to raise awareness and interest in the general community.

The challenge is not small. We are proposing nothing less than a transformation of medicine; away from the increasingly burdensome and unprofitable chase to treat pathologies, and towards a functional – and, for society as a whole, more cost-effective – approach to maintaining and extending individual health.

We hope that you will share our vision, and that you will join us on what promises to be a remarkable journey.

Contributions 
Contact information
Aubreyde GreyAubrey de Grey

Aubreyde Grey